Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Year: 2008
Type: review
Source: Journal of Immunological Methods
Authors: Eugen Koren, Holly W. Smith, Elizabeth Shores, Gopi Shankar, Deborah Finco-Kent, Bonita Rup, Yu-Chen Barrett, Viswanath Devanarayan, Boris Gorovits, Shalini Gupta, Thomas Parish, Valerie Quarmby, Michael Moxness, Steven J. Swanson, Gary Taniguchi, Linda A. Zuckerman, Christopher C. Stebbins, Anthony Mire-Sluis
Institutions: Abbott Vascular (United States), Eli Lilly (United States), United States Food and Drug Administration, Center for Drug Evaluation and Research, Pfizer (United States), Wyeth, Bristol-Myers Squibb (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Amgen (United States), Procter & Gamble (United States), Genentech, PDL BioPharma (United States)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2138572955
